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A B S T R A C T   
Objectives: In the phase III CASPIAN study, irst-line durvalumab plus etoposide in combination with either 
cisplatin or carboplatin (EP) signiicantly improved overall survival (primary endpoint) versus EP alone in pa-
tients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient- 
reported outcomes (PROs). 
Materials and methods: Treatment-naïve patients with ES-SCLC received 4 cycles of durvalumab plus EP every 3 
weeks followed by maintenance durvalumab every 4 weeks until progression, or up to 6 cycles of EP every 3 
weeks. PROs, assessed with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of 
Life Questionnaire-Core 30 (QLQ-C30) version 3 and its lung cancer module, the Quality of Life Questionnaire- 
Lung Cancer 13 (QLQ-LC13), were prespeciied secondary endpoints. Changes from baseline to disease pro-
gression or 12 months in prespeciied key disease-related symptoms (cough, dyspnea, chest pain, fatigue, 
appetite loss) were analyzed with a mixed model for repeated measures. Time to deterioration (TTD) of symp-
toms, functioning, and global health status/quality of life (QoL) from randomization was analyzed. 
Results: In the durvalumab plus EP and EP arms, 261 and 260 patients were PRO-evaluable. Patients in both arms 
experienced numerically reduced symptom burden over 12 months or until progression for key symptoms. For 
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the improvements from baseline in appetite loss, the between-arm difference was statistically signiicant, fa-
voring durvalumab plus EP (difference, −4.5; 99% CI: −9.04, −0.04; nominal p = 0.009). Patients experienced 
longer TTD with durvalumab plus EP versus EP for all symptoms (hazard ratio [95% CI] for key symptoms: cough 
0.78 [0.600‒1.026]; dyspnea 0.79 [0.625‒1.006]; chest pain 0.76 [0.575‒0.996]; fatigue 0.82 [0.653‒1.027]; 
appetite loss 0.70 [0.542‒0.899]), functioning, and global health status/QoL. 
Conclusion: Addition of durvalumab to irst-line EP maintained QoL and delayed worsening of patient-reported 
symptoms, functioning, and global health status/QoL compared with EP.   
1. Introduction 
Approximately two-thirds of patients who present with small-cell 
lung cancer (SCLC) have extensive-stage SCLC (ES-SCLC), relecting 
the highly aggressive nature of this tumor and its tendency for early, 
widespread metastasis [1,2]. Less than 5% of patients with ES-SCLC 
remain alive at 2 years after diagnosis [3]. Progress in improving out-
comes for patients with ES-SCLC has been limited until recently. Stan-
dard irst-line treatment has consisted of etoposide in combination with 
either carboplatin or cisplatin (EP) for more than three decades [4–6]. 
However, the addition of immunotherapy targeting the programmed 
cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway to 
platinum-based chemotherapy has been shown to prolong overall sur-
vival (OS) in patients with ES-SCLC [7,8]. 
Durvalumab is a selective, high-afinity human immunoglobulin G1 
monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 [9]. 
The phase III CASPIAN study (NCT03043872) is assessing the eficacy 
and safety of irst-line durvalumab, with or without the anti-cytotoxic T 
lymphocyte-associated antigen-4 antibody tremelimumab, in combina-
tion with EP versus EP alone in patients with ES-SCLC [8]. At the 
planned interim analysis, durvalumab plus EP signiicantly prolonged 
OS compared with EP (hazard ratio [HR]: 0.73; 95% conidence interval 
[CI]: 0.59–0.91; p = 0.0047) [8]. Median OS was 13.0 months in the 
durvalumab plus EP arm versus 10.3 months in the EP arm. The survival 
beneit was observed across all prespeciied, clinically relevant patient 
subgroups. Median progression-free survival (PFS) was 5.1 months in 
the durvalumab plus EP arm versus 5.4 months in the EP arm (HR: 0.78; 
95% CI: 0.65–0.94); 12-month PFS rates were 18% versus 5%. A recent 
updated analysis demonstrated the OS improvement with durvalumab 
plus EP versus EP was sustained after a median follow-up of more than 2 
years (HR: 0.75; 95% CI: 0.62‒0.91; nominal p = 0.0032) [10]. Safety 
indings were consistent with the known safety proiles of both durva-
lumab and EP. 
Prolonged survival is most meaningful if patients’ quality of life 
(QoL) is not unduly compromised; as such, patient-reported outcomes 
(PROs) were an important secondary endpoint of the CASPIAN study. 
PROs provide the patient’s perspective of their symptoms, functioning, 
and health-related QoL (HRQoL), and therefore complement objective 
investigator-assessed eficacy and safety endpoints. Patients diagnosed 
with SCLC typically present with a broad range of symptoms encom-
passing disease-related symptoms such as cough, dyspnea, chest pain, 
fatigue, and appetite loss, and signs of psychological distress such as 
anxiety and depression [11]. These symptoms may be more severe in 
patients who present with extensive-stage disease compared with earlier 
stages of disease, and can have a substantial impact on physical, 
cognitive, emotional, and social functioning. Patients with SCLC have 
worse HRQoL and PROs compared with the general population [12,13]. 
Furthermore, a systematic literature review has suggested that the 
impact of SCLC on HRQoL may be greatest in patients with treat-
ment-naïve extensive-stage disease [13]. 
Here, we present PRO data from the interim analysis of the CASPIAN 
study, to assess the effect of adding durvalumab to EP as irst-line 
treatment for ES-SCLC on patients’ symptoms, functioning, and HRQoL. 
2. Methods 
2.1. Study design and patients 
CASPIAN is a randomized, open-label, sponsor-blind, multicenter, 
global phase III study. Eficacy and safety results from this interim 
analysis (data cutoff: March 11, 2019) have been reported previously, 
and the study methodology is described in detail in the primary report 
[8]. Briely, eligible patients were aged ≥18 years and had treatment--
naïve histologically or cytologically documented ES-SCLC, World Health 
Organization (WHO) performance status score of 0 or 1, and measurable 
disease according to Response Evaluation Criteria in Solid Tumors, 
version 1.1 [14]. Patients with brain metastases were eligible provided 
they were asymptomatic or treated and stable and had been off steroids 
and anticonvulsants for at least 1 month prior to study entry. 
The study was conducted in accordance with the International 
Conference on Harmonisation good clinical practice guidelines, the 
Declaration of Helsinki, and applicable local regulations with approval 
from an independent ethics committee or institutional review boards. 
The protocol and all modiications were approved by relevant ethics 
committees and regulatory authorities. 
2.2. Treatment 
Patients were randomized in a 1:1:1 ratio to receive durvalumab plus 
EP, durvalumab plus tremelimumab plus EP, or EP. Randomization was 
stratiied by planned platinum agent (carboplatin or cisplatin). All drugs 
were administered intravenously. EP in each arm consisted of etoposide 
80‒100 mg/m2, administered on days 1–3 of each 21-day cycle, and 
investigator’s choice of either carboplatin area under the curve 5‒6 mg/ 
mL/min or cisplatin 75‒80 mg/m2, administered on day 1 of each cycle. 
Patients in the immunotherapy arms received EP plus durvalumab 
1500 mg, with or without tremelimumab 75 mg, every 3 weeks for 4 
cycles, followed by maintenance durvalumab 1500 mg every 4 weeks. 
Immunotherapies were administered on day 1 of each cycle. Patients in 
the EP arm could receive an additional 2 cycles of EP (up to 6 cycles in 
total) as well as prophylactic cranial irradiation (PCI) post-EP at the 
investigator’s discretion. Patients continued treatment until disease 
progression per investigator assessment, unacceptable toxicity, or other 
discontinuation criteria were met. Patients could continue study treat-
ment beyond disease progression if the investigator judged them to be 
deriving clinical beneit. 
2.3. Endpoints and assessments 
The primary endpoint was OS. Secondary endpoints included PFS, 
objective response rate, safety and tolerability, as well as PROs (the 
focus of this article). Prespeciied secondary PRO endpoints comprised 
measurement of symptoms, functioning, and HRQoL. The symptoms of 
appetite loss, constipation, diarrhea, dyspnea, fatigue, nausea or vom-
iting, pain, and insomnia; functioning (physical, cognitive, emotional, 
role, and social); and global health status/QoL were assessed using the 
European Organisation for Research and Treatment of Cancer (EORTC) 
30-item core Quality of Life Questionnaire, version 3 (QLQ-C30 v3) 
[15]. Additional lung cancer-associated symptoms of cough, dyspnea, 
hemoptysis, arm or shoulder pain, chest pain, and other pain were 
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assessed using the EORTC 13-item lung cancer module (QLQ-LC13) 
[16]. Cough, dyspnea, and chest pain from QLQ-LC13, and fatigue and 
appetite loss from QLQ-C30 were predeined as primary measures of 
interest (key disease-related symptoms) based on a review of the liter-
ature and qualitative interviews with clinicians and patients to discuss 
their experiences related to ES-SCLC and its treatment [11]. Data 
regarding the inancial dificulties item from the QLQ-C30 questionnaire 
and side-effects from conventional chemoradiotherapy (sore mouth, 
dysphagia, peripheral neuropathy, and alopecia) from the QLQ-LC13 
module will not be reported. 
The two questionnaires were administered to patients independently 
on a handheld electronic device during clinic visits, before any other 
study procedures. Questions could not be skipped on the device and thus 
it was not possible to submit a partially completed form. The ques-
tionnaires were completed at baseline and on the irst day of each 
treatment cycle, or (for patients who discontinued treatment before 
progression) every 4 weeks, until disease progression. As disease pro-
gression often precipitates a deterioration in patient HRQoL, patients 
were also required to complete questionnaires on day 28 after pro-
gression, and thereafter every 8 weeks until second progression or death 
(whichever came irst). 
2.4. Statistical analysis 
Summary statistics were compiled for overall compliance and 
compliance over time for both questionnaires. Scores for the QLQ-30 
and QLQ-LC13 questionnaires were calculated according to published 
scoring manuals or the developer’s guidelines. Raw scores from scales in 
both questionnaires are standardized by linear transformation so that 
they range from 0 to 100. Higher scores for symptom items indicate 
greater symptom severity, while higher scores for function and global 
health status/QoL items indicate better function and health status/QoL. 
For both questionnaires, a clinically meaningful change was prespeciied 
as an absolute change in score from baseline of ≥10 points (either 
deterioration or improvement) [17]. 
For the ive key disease-related symptoms (cough, dyspnea, and 
chest pain [QLQ-LC13], and fatigue and appetite loss [QLQ-C30]), 
changes at each visit from baseline to disease progression or 12 
months (whichever came irst) were analyzed using a mixed model for 
repeated measures (MMRM) to derive an overall adjusted mean change 
from baseline, relecting the average treatment effect over visits. The 
model assumes PROs were collected at multiple visits per patient and 
that data are missing at random. Visits with >75% missing data were 
excluded from the analysis. The MMRM included treatment, age at 
randomization (<65 vs ≥65 years), sex, smoking history (smoker vs 
non-smoker), visit, and treatment-by-visit interaction as ixed factors, 
and baseline score as a covariate; the model further adjusted for baseline 
score-by-visit interaction. PROs were not part of the multiple-testing 
procedure in CASPIAN and, as such, no alpha was allocated to the 
analysis of PRO endpoints and all p-values reported are nominal. How-
ever, the overall type I error (5% 2-sided) was controlled across the 
MMRM analysis for each of the ive key symptoms using a Bonferroni 
adjusted 1% signiicance level and 99% CIs. 
Time to deterioration (TTD) was assessed in patients whose baseline 
scores were ≥10 for functioning and global health status/QoL and ≤90 
for symptoms. TTD was deined as the time from randomization to the 
irst clinically meaningful deterioration (≥10-point increase from 
baseline for symptoms; ≥10-point decrease from baseline for function 
and global health status/QoL) that was conirmed at a subsequent 
assessment, or death from any cause in the absence of clinically mean-
ingful deterioration. Patients with a single deterioration and no further 
assessments were treated as deteriorated. The Kaplan-Meier method was 
used to estimate TTD, which was analyzed using a stratiied log-rank test 
adjusting for planned platinum therapy (carboplatin or cisplatin), with 
HRs and 95% CIs calculated using a stratiied Cox proportional hazards 
model. 
PRO analyses were to be performed in all randomized patients (i.e. 
the intent-to-treat [ITT] population). However, patients randomized at 
one site were excluded from these analyses as their PRO data could not 
be veriied, and therefore the PRO-evaluable population consisted of the 
ITT population minus the patients randomized at this site. 
Data underlying the indings described in this manuscript may be 
obtained in accordance with AstraZeneca’s data sharing policy 
described at https://astrazenecagrouptrials.pharmacm.com/ST/Subm 
ission/Disclosure. 
3. Results 
3.1. Patients 
In total, 972 patients were enrolled into the study between March 
2017 and May 2018, with 805 patients randomized to durvalumab plus 
EP (n = 268), durvalumab plus tremelimumab plus EP (n = 268), or EP 
alone (n = 269) [8] (Supplementary Fig. 1). The ITT population at this 
interim analysis included all 537 patients randomized to the durvalu-
mab plus EP and EP arms. As previously reported, baseline de-
mographics and disease characteristics were well balanced between 
treatment arms [8]. In the durvalumab plus EP and EP arms, 261 and 
260 patients were evaluable for PRO analyses; this represents the ITT 
population minus 16 patients at one site who were excluded speciically 
from PRO analyses as their PRO data could not be veriied. 
3.2. QLQ-C30 and QLQ-LC13 compliance and baseline scores 
Baseline QLQ-C30 data were available for 245 patients (94%) in each 
arm, and baseline QLQ-LC13 data were available for 244 patients (93%) 
in the durvalumab plus EP arm and 245 patients (94%) in the EP arm. 
For both questionnaires, compliance rates were >60% for up to cycle 23 
in the durvalumab plus EP arm and up to cycle 7 in the EP arm (Sup-
plementary Fig. 2A and B). Compliance during post-progression follow- 
up was more variable, but generally better in the durvalumab plus EP 
arm, compared with the EP arm (Supplementary Fig. 2C and D). 
Baseline QLQ-C30 and QLQ-LC13 scores for global health status/ 
QoL, functioning, and symptoms were generally comparable between 
treatment arms (Supplementary Fig. 3). Mean baseline scores for global 
health status/QoL were 56.0 in the durvalumab plus EP arm and 54.1 in 
the EP arm; for physical functioning, the scores were 72.2 and 70.7, 
respectively. In terms of symptoms, mean baseline scores with durva-
lumab plus EP and EP were 28.4 and 29.5 for pain, and 24.2 and 25.6 for 
appetite loss. The most severe symptoms at baseline (mean score ≥30) 
were cough (41.5 in the durvalumab plus EP arm and 40.5 in the EP 
arm), dyspnea (QLQ-C30: 36.5 and 38.5; QLQ-LC13: 30.7 and 31.8), 
fatigue (35.3 and 37.1), and insomnia (29.7 and 33.9). Low baseline 
values (mean score <10) were reported for diarrhea (4.9 and 5.6), 
nausea or vomiting (5.6 and 6.9), and hemoptysis (6.3 and 5.3). Baseline 
scores on the QLQ-C30 functioning scales from patients in both treat-
ment arms were comparable to available reference values for patients 
with ES-SCLC; however, baseline scores for lung cancer-associated 
symptoms (cough, dyspnea, arm or shoulder pain, chest pain, other 
pain) from QLQ-LC13 in both arms were worse compared with a 
normative sample of patients with SCLC [12]. 
3.3. Changes from baseline 
The MMRM analysis of adjusted mean change from baseline to dis-
ease progression or 12 months averaged over visits showed that patients 
in both arms experienced a numerically reduced symptom burden for 
each of the key disease-related symptoms (Fig. 1). The improvement in 
appetite loss from baseline was signiicantly greater in the durvalumab 
plus EP arm as compared with the EP arm (adjusted mean change from 
baseline: −12.7 vs −8.2; estimated difference: −4.5; 99% CI: −9.04, 
−0.04; nominal p = 0.009). Adjusted mean changes from baseline were 
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similar across both arms for the other key symptoms of cough (−17.1 in 
the durvalumab plus EP arm and −17.1 in the EP arm), dyspnea (QLQ- 
LC13: −8.6 and −8.0), chest pain (−8.1 and −9.4), and fatigue (−7.4 
and −5.6). Unadjusted mean changes from baseline over time in global 
health status/QoL, physical functioning, cognitive functioning, and the 
ive prespeciied key disease-related symptoms are shown in Supple-
mentary Fig. 4. 
3.4. Time to deterioration 
Longer median TTD was observed for patients in the durvalumab 
plus EP arm compared with those in the EP arm for global health status/ 
QoL and all functioning scales, as well as for all QLQ-C30 and QLQ-LC13 
symptom scales (Fig. 2). HRs favored durvalumab plus EP versus EP, 
with upper bounds of 95% CIs <1 for all functioning domains, as well as 
for symptoms including appetite loss, constipation, diarrhea, dyspnea, 
and insomnia (QLQ-C30), and hemoptysis, arm or shoulder pain, chest 
pain, and other pain (QLQ-LC13). Kaplan-Meier curves for TTD in the 
key disease-related symptoms of cough, dyspnea, chest pain, fatigue, 
and appetite loss are shown in Fig. 3. Kaplan-Meier curves for TTD in 
global health status/QoL, functioning scales, and other symptoms are 
shown in Supplementary Figs. 5 and 6. 
4. Discussion 
First-line treatment with durvalumab plus EP was associated with a 
statistically signiicant and clinically meaningful improvement in OS 
compared with EP alone in patients with ES-SCLC, with an HR of 0.73 
(95% CI: 0.59–0.91; p = 0.0047), as previously reported [8]. Clinical 
beneit with durvalumab plus EP was also observed across the secondary 
Fig. 1. MMRM analysis of adjusted mean 
change from baseline to disease progression or 
12 months in prespeciied key disease-related 
symptoms. 
Presented are adjusted mean changes from 
baseline (bars), and between-arm differences 
(Δ), with 99% CIs. A negative difference (Δ) 
favors durvalumab plus EP versus EP alone. CI, 
conidence interval; EP, platinum-etoposide; 
ITT, intention-to-treat; MMRM, mixed model 
for repeat measures; QLQ-C30, Quality of Life 
Questionnaire-Core 30; QLQ-LC13, Quality of 
Life Questionnaire-Lung Cancer 13.   
Fig. 2. Time to deterioration in global health status/QoL, functioning, and symptoms. 
The analysis population includes patients with baseline scores ≥10 for the QLQ-C30 functional scales and global health status/QoL and patients with baseline scores 
≤90 for the QLQ-C30 and QLQ-LC13 symptom scales/items. An HR < 1.0 indicates longer TTD with durvalumab plus EP versus EP alone. CI, conidence interval; EP, 
platinum-etoposide; HR, hazard ratio; OS, overall survival; QLQ-C30, Quality of Life Questionnaire-Core 30; QLQ-LC13, Quality of Life Questionnaire-Lung Cancer 
13; QoL, quality of life; TTD, time to deterioration. 
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endpoints of PFS and objective response rate. Safety indings were 
consistent with the established safety proiles of both durvalumab and 
EP, and most immune-mediated adverse events (AEs) were low grade 
and manageable with standard treatment guidelines. In addition to ef-
icacy, symptom control is an important element of therapeutic objec-
tives in advanced lung cancer, where life expectancy is generally limited 
with potentially high symptom burden and low QoL [18]. We evaluated 
patient-reported symptoms, function, and HRQoL in the CASPIAN study 
to understand the impact of the disease and treatment from the patient 
perspective and ensure that clinical beneits do not come at the cost of 
impaired QoL. 
In the CASPIAN study, the PRO results demonstrated that durvalu-
mab plus EP maintained QoL while signiicantly improving OS in ES- 
SCLC. The MMRM analysis showed that patients treated with both 
durvalumab plus EP and EP alone experienced a numerically reduced 
symptom burden over a period of 12 months or until disease progression 
for the key disease-related symptoms of cough, dyspnea, chest pain, 
fatigue, and appetite loss. There was a statistically signiicant difference 
between arms in favor of durvalumab plus EP for the improvements 
from baseline in appetite loss, which may relect improved tumor con-
trol without substantially increased toxicity. Consistent with eficacy 
outcomes, durvalumab plus EP delayed worsening of patient-reported 
Fig. 3. Kaplan-Meier analysis of time to deterioration in prespeciied key disease-related symptoms of (A) cough, (B) dyspnea, (C) chest pain, (D) fatigue, and (E) 
appetite loss. 
The analysis population includes patients with baseline scores ≥10 for the QLQ-C30 functional scales and global health status/QoL and patients with baseline scores 
≤90 for the QLQ-C30 and QLQ-LC13 symptom scales/items. An HR < 1.0 indicates longer TTD with durvalumab plus EP versus EP alone. p-values presented are 
nominal. CI, conidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; ITT, intention-to-treat; QLQ-C30, Quality of Life Questionnaire-Core 30; 
QLQ-LC13, Quality of Life Questionnaire-Lung Cancer 13. 
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symptoms (including the ive prespeciied key disease-related symp-
toms), as well as all ive patient functioning domains, and global health 
status/QoL, compared with EP. 
The prolonged TTD observed with the addition of durvalumab to EP 
may relect the longer OS, PFS, and duration of response observed in this 
arm in CASPIAN [8]. Similar to PFS, the TTD Kaplan-Meier curves 
separated between 4 cycles and 6 cycles across many PRO domains. This 
is consistent with the immediate expected effects of chemotherapy and 
the likely prolonged effects of immunotherapy on PROs. PROs were also 
collected beyond initial progression, up to second disease progression, to 
better characterize patient experience over a longer period. The TTD 
results suggest that treatment beneit with durvalumab plus EP 
compared to EP alone may be sustained beyond initial disease 
progression. 
The analysis of changes from baseline in key disease-related symp-
toms showed an improvement in symptoms over time in both arms, but 
the effect was modest. This may be because patients enrolled in CAS-
PIAN had a relatively good performance status (WHO performance 
status score of 0 or 1 was an eligibility criterion). Further, interpretation 
of the MMRM analysis of change from baseline was limited as the 
analysis model only accounted for data until initial disease progression, 
which occurred at ~5 months for over half of the patients. 
In CASPIAN, PRO analyses were focused primarily on lung cancer 
symptoms, whereas investigator-assessed AEs were largely driven by 
treatment-related side-effects, so a direct relationship between PROs 
and safety is not necessarily anticipated. However, PROs complement 
physician-reporting of safety to better characterize treatment tolera-
bility and its impact on QoL [19]. Safety data from CASPIAN showed the 
incidences of any AEs, grade 3 or 4 AEs, AEs leading to discontinuation, 
and AEs leading to death were similar across both treatment arms; the 
most common AEs were hematological toxicities associated with 
chemotherapy [8]. The incidence of serious AEs was slightly higher in 
the EP arm (36% of patients) compared with the durvalumab plus EP 
arm (31% of patients), possibly due to the increased number of cycles of 
EP received in the control arm. The type, incidence, and severity of AEs 
reported were consistent with the known safety proiles of both durva-
lumab and EP. As expected, immune-mediated AEs were more frequent 
in the durvalumab plus EP arm. However, the mainly low grade and 
manageable nature of these events, which were predominantly endo-
crine in nature, did not appear to have a clinically meaningful impact on 
PROs. 
Despite the substantial symptom burden and poor outcomes associ-
ated with SCLC, the literature reporting PROs in this population is sparse 
[13]. To our knowledge, the IMpower133 study is the only other ran-
domized study of immunotherapy targeting the PD-1/PD-L1 pathway 
for the treatment of patients with ES-SCLC from which PRO data are 
available [20]. Results of this double-blind, placebo-controlled study 
showed no increase in symptom burden with atezolizumab added to 
carboplatin-etoposide compared with placebo plus 
carboplatin-etoposide in patients with ES-SCLC. With the exception of 
dyspnea, improvements in TTD of lung cancer symptoms were not 
observed with the addition of atezolizumab [20]. Differences from 
CASPIAN in the study design, treatment, and schedule of PRO assess-
ments should be considered when interpreting these results. 
Potential limitations of the PRO analyses presented here include the 
open-label trial design, which could lead to reporting bias. However, 
symptoms and certain domains such as physical functioning that are 
directly impacted by disease physiology and treatment are likely to be 
less subject to open-label bias compared with domains such as emotional 
functioning that could be inluenced by additional factors such as socio- 
economic [21]. The PRO results are supported by other objective mea-
sures of eficacy, including the superior OS observed with durvalumab 
plus EP versus EP. The robustness of the indings is demonstrated by the 
consistent beneit observed in TTD with durvalumab plus EP versus EP 
across all symptoms and functioning domains. 
Interpretation of the CASPIAN PROs data may also be limited by the 
divergence in compliance rates between the treatment arms. The sample 
size in the EP arm was markedly lower than that in the durvalumab plus 
EP arm from approximately week 24 onwards, and it is possible this 
indicates data are not missing at random. Reduced compliance in the EP 
arm is unsurprising due to the shorter duration of treatment in the EP 
arm compared with the durvalumab plus EP arm, in which patients 
received maintenance durvalumab post-EP. Following completion of 
study treatment, patients may have had a reduced level of engagement 
with study procedures and been less motivated to complete question-
naires. It is possible that the smaller amount of PRO data from the EP 
arm would bias the results in favor of the EP arm, if non-compliance was 
associated with declining function or increased symptom burden. 
Conversely, the larger amount of missing data on the EP arm could result 
in an opposite bias owing to under-representation of the EP arm during 
the later visits where scores are improved. 
Other limitations include a potential confounding effect of PCI, 
which was permitted only in the control arm. A prior phase III trial 
showed a short-term negative impact of PCI on selected HRQOL scales in 
patients with ES-SCLC [22]. However, as only 8% of patients in the EP 
arm in CASPIAN received PCI [8], any effect is likely to have been 
minimal. Finally, the EORTC QLQ-C30 and QLQ-LC13 questionnaires 
were designed in the era of chemotherapy and, although they have since 
been used in many clinical trials of immunotherapy in lung cancer, 
certain side effects of modern-day immunotherapy are not covered by 
them. They are, however, the most frequently used instruments in lung 
cancer research and have been extensively tested and validated [23]. 
In conclusion, the addition of durvalumab to EP in the CASPIAN trial 
appeared to have no additional detrimental impact on PROs. First-line 
durvalumab plus EP provided a meaningful patient-centered beneit 
by signiicantly prolonging survival in patients with ES-SCLC, while 
preserving their QoL and delaying worsening of patient-reported 
symptoms, functioning, and HRQoL compared with EP. 
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